Athira’s Fosgonimeton Fails In Phase II/III LIFT-AD Trial, Future Uncertain
Phase I Next-Gen Drug May Become Priority
The company said that while its drug did not achieve statistical significance on any endpoints in the Alzheimer’s study, improvements favoring fosgonimeton showed potential for HGF modulation.
